Closed transaction
- Advised by
- Client
-
- Counterparty
-
- Deal stage
- Closed transaction
- Service
- Sell
- Sector
- Healthcare
- Contact
- aodin@ddacompany.com
Deal details
DDA & Company represented the shareholders of Hyphen BioMed SAS, a scientific company boasting an extended experience in the field of Thrombosis, Haemostasis and Auto-Immunity providing a comprehensive offering of diagnostic and research reagents, distributed worldwide, on its sale to Japanese listed Sysmex Corporation
DDA & Company latest deals
Sell-side advisory
Ghost Controls was sold to Assa Abloy.
- Adviser
- DDA & Company
- Where
- United States of America
- Year
- 2023
Buy-side advisory
Nutricia acquired Real Food Blends.
- Adviser
- DDA & Company
- Where
- United States of America
- Year
- 2020
Sell-side advisory
Extens, Capital Croissance, Bpifrance acquired Albus (SNAL).
- Adviser
- DDA & Company
- Where
- United States of America
- Year
- 2017
Buy-side advisory
4ventsgroup acquired Meanings.
- Adviser
- DDA & Company
- Where
- United States of America
- Year
- 2017
More deals in Healthcare
Sell-side advisory
NUTRIBRAIN was sold to LABORATORIOS RUBIÓ.
- Adviser
- INEO Corporate
- Where
- Spain
- Year
- 2026
Sell-side advisory
PharmaX Solutions was sold to BioPhorum.
- Adviser
- Hoffmann & Partner
- Where
- Switzerland
- Year
- 2026
Sell-side advisory
Nostos Genomics was sold to Limbus Medical Technologies (varvis®).
- Adviser
- Hoffmann & Partner
- Where
- Switzerland
- Year
- 2025
Sell-side advisory
3iM Healthcare AB acquired Avia Pharma.
- Adviser
- Evli Corporate Finance AB
- Where
- Finland
- Year
- 2025
More deals in Asia-Pacific
Membership
Gain worldwide reach with CapFive M&A professionals
The professionals of CapFive have been carefully selected on the basis of reputation, relationships, proven track record and knowledge of local markets.
Become a member